Parc Technologique de Lyon
8, allée Irène Joliot Curie
Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’Up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life.
CEO: Étienne Binant
CMO: William Spotnitz
CSO: Valerie Centis
CFO: Joao-Paulo Alves
6 articles with Biom'up
Biom’up is providing for the first time, full-year 2019 guidance for global sales of HEMOBLAST Bellows in the range of €4.0-4.5 million.
Biom'up announced its full-year results for the year ending December 31, 2018, as approved by the Company's Board of Directors on April 29, 2019, and provided an update on its operations.
Biom’up announced that the U.S. Food and Drug Administration approved the IDE application for HEMOSNOW, a hemostatic dry powder made from porcine collagen and bovine-derived chondroitin sulfate developed by the Company for managing minimal and mild levels of bleeding during surgical procedures.
Biom’up announces first US sales in laparoscopy for HEMOBLASTTM Bellows and the signing of an exclusive distribution agreement for HEMOBLASTTM Bellows in Australia
Major framework agreement signed with Life Healthcare Distribution (“LHC”) for the exclusive distribution of HEMOBLAST Bellows in the sizeable and growing Australian market
Biom'up completes its Board of Directors with the nomination of Dr. Peter Byloos to support its international growth
Biom'up today announces Dr. Peter Byloos' co-optation to its Board of Directors as an independent director.
Biom'Up announces today that it has received FDA marketing approval for HEMOBLAST Bellows, its flagship product, 7 months ahead of schedule.